My Personal Therapeutics is a London based biotechnology company offering cancer patients worldwide access to the most advanced personalised cancer therapeutics based on technology pioneered at The Mount Sinai School of Medicine, New York.
The technology, known as the Personal Discovery Process (PDP), backed by the American Cancer Society and with technical input from the FDA, was developed to effectively address the finding that real-world patient tumours are made resistant to single-drug treatments. PDP targets the unique genetic complexity of each patient's tumour to identify the precise combination of drugs that works optimally on the patient's specific tumour.
We work with cancer patients and oncologists globally to ensure they are supported throughout the PDP process.
The PDP methods are licensed exclusively to My Personal Therapeutics.